Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial

Introduction: KidneyIntelX is a composite risk score, incorporating biomarkers and clinical variables for predicting progression of diabetic kidney disease (DKD). The utility of this score in the context of sodium glucose co-transporter 2 inhibitors and how changes in the risk score associate with future kidney outcomes are unknown. Methods: We measured soluble tumor necrosis factor receptor (TNFR)-1, soluble TNFR-2, and kidney injury molecule 1 on banked samples from CANagliflozin cardioVascular Assessment Study (CANVAS) trial participants with baseline DKD (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2 or urine albumin-to-creatinine ratio [UACR] ≥30 mg/g) and generated KidneyIntelX risk scores at baseline and years 1, 3, and 6. We assessed the association of baseline and changes in KidneyIntelX with subsequent DKD progression (composite outcome of an eGFR decline of ≥5 mL/min/year [using the 6-week eGFR as the baseline in the canagliflozin group], ≥40% sustained decline in the eGFR, or kidney failure). Results: We included 1,325 CANVAS participants with concurrent DKD and available baseline plasma samples (mean eGFR 65 mL/min/1.73 m2 and median UACR 56 mg/g). During a mean follow-up of 5.6 years, 131 participants (9.9%) experienced the composite kidney outcome. Using risk cutoffs from prior validation studies, KidneyIntelX stratified patients to low- (42%), intermediate- (44%), and high-risk (15%) strata with cumulative incidence for the outcome of 3%, 11%, and 26% (risk ratio 8.4; 95% confidence interval [CI]: 5.0, 14.2) for the high-risk versus low-risk groups. The differences in eGFR slopes for canagliflozin versus placebo were 0.66, 1.52, and 2.16 mL/min/1.73 m2 in low, intermediate, and high KidneyIntelX risk strata, respectively. KidneyIntelX risk scores declined by 5.4% (95% CI: −6.9, −3.9) in the canagliflozin arm at year 1 versus an increase of 6.3% (95% CI: 3.8, 8.7) in the placebo arm (p < 0.001). Changes in the KidneyIntelX score at year 1 were associated with future risk of the composite outcome (odds ratio per 10 unit decrease 0.80; 95% CI: 0.77, 0.83; p < 0.001) after accounting for the treatment arm, without evidence of effect modification by the baseline KidneyIntelX risk stratum or by the treatment arm. Conclusions: KidneyIntelX successfully risk-stratified a large multinational external cohort for progression of DKD, and greater numerical differences in the eGFR slope for canagliflozin versus placebo were observed in those with higher baseline KidneyIntelX scores. Canagliflozin treatment reduced KidneyIntelX risk scores over time and changes in the KidneyIntelX score from baseline to 1 year associated with future risk of DKD progression, independent of the baseline risk score and treatment arm.

[1]  K. Mahaffey,et al.  Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial , 2021, Diabetologia.

[2]  M. Kattan,et al.  Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease , 2021, Diabetologia.

[3]  T. Goss,et al.  Payer budget impact of an artificial intelligence in vitro diagnostic to modify diabetic kidney disease progression , 2021, Journal of medical economics.

[4]  R. Vasan,et al.  Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2020, Journal of the American Society of Nephrology : JASN.

[5]  K. Mahaffey,et al.  Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  K. Mahaffey,et al.  Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. , 2020, Journal of the American Society of Nephrology : JASN.

[7]  John Quackenbush,et al.  Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes. , 2020, Kidney360.

[8]  P. Kimmel,et al.  Plasma Biomarkers of Tubular Injury and In fl ammation Are Associated with CKD Progression in Children , 2020 .

[9]  K. Mahaffey,et al.  Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. , 2019, Journal of the American Society of Nephrology : JASN.

[10]  Deepak L. Bhatt,et al.  Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD). , 2019, Circulation.

[11]  A. Heinzel,et al.  Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease , 2019, Diabetologia.

[12]  K. Mahaffey,et al.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.

[13]  B. Kestenbaum,et al.  Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis. , 2018, Journal of the American Society of Nephrology : JASN.

[14]  R. Guthrie Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[15]  L. Fried,et al.  Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[16]  K. Mahaffey,et al.  Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials , 2017, Diabetes, obesity & metabolism.

[17]  G. Nadkarni,et al.  Biomarkers for predicting outcomes in chronic kidney disease , 2016, Current opinion in nephrology and hypertension.